SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines (LUNR) is trending as the community eagerly anticipates the multi-billion dollar NASA Lunar Terrain Vehicle (LTV) contract award and upcoming earnings, following its recent $175 million strategic equity investment and the integration of its Lanteris acquisition. High short interest and broader enthusiasm for the "moon economy" are fueling significant volatility and debate around the stock's future in space infrastructure.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as the market anticipates its pivotal Q4 earnings report, with sentiment sharply divided between expectations of a blowout performance driving new highs and concerns over a potential "sell the news" event. Discussions are also active around the future of AI demand, competition, and the upcoming Rubin AI system.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending following its strong earnings report, showcasing surging stablecoin demand and USDC circulation growth, igniting community debate around a potential short squeeze and its foundational role in digital finance, while others remain cautious given valuation concerns and ongoing regulatory hurdles.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to highly polarized reactions to Donald Trump's recent State of the Union address, where community discussion is intensely divided over his political rhetoric, economic claims, and controversy surrounding the Epstein files; this has investors and commentators sharply split between those celebrating the speech as a success that will drive the stock and those criticizing it as a "lie-a-thon" underscoring the company's speculative fundamentals.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is trending due to anticipation surrounding its upcoming Q4 earnings and business update, with positive sentiment driven by partner United Therapeutics' strong Tyvaso DPI sales and the potential for Afrezza's pediatric FDA approval. The community is actively discussing future catalysts, including upcoming Teton-1 study results and the implications of competing inhaler technologies.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following recent announcements of an innovation hub in India and a new "Sales Assist" agent, all ahead of its highly anticipated earnings report. Community discussion is focused on strong expectations for revenue growth and a path to profitability, with high short interest fueling speculation of a potential squeeze for its patented voice AI technology across automotive, QSR, and enterprise sectors.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending following its earnings report, which highlighted its consistent "beat and raise" streak and AI-powered marketing platform's strong performance, sparking community discussion about its undervalued position despite ongoing software sector sell-offs.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is trending after projecting a significant revenue decline for its upcoming quarter, sparking a sharp sell-off and contrasting with its history of strong financial performance. The community is actively debating if the market reaction is an overcorrection and a buying opportunity, given the company's share buyback program, or if the stock faces further downside amidst an undefined bottom.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is trending after its 2026 sales guidance fell below consensus, prompting analyst downgrades and a stock decline. The community is actively debating if this creates a buying opportunity, weighing the near-term outlook against the company's strong US manufacturing position and potential tailwinds from AI data center energy demand.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is trending down sharply after its latest earnings report, despite beating EPS and revenue estimates, as cautious fiscal year 2027 revenue guidance amplifies broader market concerns about AI's disruptive impact on the software sector. The community is actively debating if the current sell-off is an overreaction to strong underlying fundamentals or a justified repricing given the evolving landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Immunic Announces Closing of Oversubscribed Private Placement Financing

Immunic Announces Closing of Oversubscribed Private Placement Financing Immunic Announces Closing of Oversubscribed Private Placement Financing PR Newswire NEW YORK, Feb. 17, 2026 Upfront Proceeds of...

Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push

In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.Shares of Immunic, Inc. (Nasdaq: IMUX) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for ...

D. Boral Capital Lowers Immunic (NASDAQ:IMUX) Price Target to $4.00

D. Boral Capital cut their price target on shares of Immunic from $8.00 to $4.00 and set a "buy" rating for the company in a research note on Friday...

<ul class="summary-bullets"><li>Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs.</li><li>The company said that it&nbsp;is preparing to shift from a development-focused biotech into a commercial-stage company.</li><li>Immunic looks to prioritize its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026.</li></ul>Immunic Inc. (IMUX) announced on Friday that it has secured a private placement that could generate up to $400 million in gross proceeds, providing funding to advance its multiple sclerosis programs and support future product launches.The financing, led by existing investor BVF Partners and including several institutional backers, includes $200 million in upfront proceeds and the potential for an additional $200 million if warrants are exercised.&nbsp;The transaction is expected to close around February 17, pending customary conditions.<h2 class="st-heading-2">Financing To Advance Clinical Studies</h2>Immunic plans to use the money raised to support its clinical studies, day-to-day operations, and other general business needs. Together with its existing cash and investments, the funds are expected to cover operating and capital costs through the end of 2027.The company said that it&nbsp;is preparing to shift from a development-focused biotech into a commercial-stage company.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/IMUX">Immunic stock</a> traded over 33% higher in Friday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<h2 class="st-heading-2">Multiple Sclerosis Programs Take Priority&nbsp;</h2>Immunic plans complete its Phase 3 ENSURE studies evaluating vidofludimus calcium in relapsing multiple sclerosis, with top-line results anticipated by year-end 2026. The company aims to file a New Drug Application in mid-2027 and, if approved, launch in 2028. It also intends to initiate a Phase 3 program in primary progressive multiple sclerosis later this year, a trial projected to run up to four years.<blockquote>“The proceeds from the initial closing are expected to provide sufficient runway through submission of an NDA in the United States in mid-2027 and to start preparations for the potential launch of vidofludimus calcium in RMS, as well as initiation of a phase 3 clinical program in PPMS.”-Daniel Vitt, CEO, Immunic</blockquote>Vitt will begin a search for a CEO to lead the next phase of growth. Vitt plans to transition into a senior strategic role while remaining on the board.IMUX stock has declined by 9% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/aap-stock-surges-pre-market-what-s-fueling-the-rally/cZR5s0pR4sw">AAP Stock Surges 9% Pre-Market – What’s Fueling the Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did IMUX Stock Surge 33% Pre-Market Today? 

Immunic announced a private placement of up to $400 million to support its clinical studies and other operational needs.  

Equity

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company Immunic Announces Oversubscribed Private Placement of up to USD...

HC Wainwright Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX)

HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Immunic in a research report on Monday...

Brookline Cap M Predicts Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Brookline Cap M issued their FY2025 EPS estimates for shares of Immunic in a research note issued to investors on Tuesday, February 3rd. Brookline Cap M...

Immunic (NASDAQ:IMUX) Upgraded at Brookline Cap M

Brookline Cap M raised shares of Immunic to a "strong-buy" rating in a research note on Tuesday...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

Immunic Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.09	--	--	N/A
Q3 '25	-$0.14	-$0.13	9.30%	BEAT
Q2 '25	-$0.16	-$0.20	-26.74%	MISSED
Q1 '25	-$0.25	--	--	N/A
Q4 '24	-$0.23	--	--	N/A

IMUX
Immunic Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest IMUX News

IMUXImmunic Inc